Immutep Secures A$652K ARC Grant for LAG-3 Research with Monash University

  • Immutep and Monash University received a A$652,248 ARC Linkage Projects grant for LAG-3 research over three years.
  • The grant builds on prior collaboration that led to the first crystal structure of the human LAG-3/MHC Class II complex.
  • Professor Jamie Rossjohn will lead the project, investigating LAG-3's role in immune regulation and the impact of IMP761.
  • Immutep will contribute financially and scientifically, though neither the ARC funding nor Immutep’s contribution is material to the company.

The ARC grant underscores the strategic importance of LAG-3 in immunotherapy, reinforcing Immutep's leadership in the space. The collaboration with Monash University highlights the growing trend of academia-industry partnerships driving fundamental research in biotech. While the funding is not material, it strengthens Immutep's scientific foundation for future therapeutic innovations.

Scientific Breakthroughs
Whether the research will yield new insights into LAG-3's immune regulatory mechanisms, potentially advancing therapeutic applications.
Strategic Collaboration
The depth of Immutep's long-term partnership with Monash University and its impact on future research initiatives.
Therapeutic Development
The pace at which structural biology findings translate into clinical-stage innovations for cancer and autoimmune therapies.